Semantic Scholar
Open Access
2022
49 sitasi
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis
K. Gordon
R. Langley
R. Warren
Y. Okubo
L. S. Stein Gold
+6 lainnya
Abstrak
Key Points Question What is the 2-year safety profile of bimekizumab in patients with moderate to severe plaque psoriasis? Findings In this cohort study including 1789 patients receiving bimekizumab, pooled data on 2 years of study treatment from 4 phase 2 randomized clinical trials and 4 phase 3 randomized clinical trials identified no safety signals. The incidence of adverse events did not increase with longer duration of exposure to bimekizumab. Meaning These results, pooled to include 2 years of treatment, suggest that bimekizumab is well tolerated among patients with moderate to severe plaque psoriasis.
Topik & Kata Kunci
Penulis (11)
K
K. Gordon
R
R. Langley
R
R. Warren
Y
Y. Okubo
L
L. S. Stein Gold
J
J. Merola
L
L. Peterson
K
K. Wixted
N
N. Cross
D
D. Deherder
D
D. Thaçi
Akses Cepat
Informasi Jurnal
- Tahun Terbit
- 2022
- Bahasa
- en
- Total Sitasi
- 49×
- Sumber Database
- Semantic Scholar
- DOI
- 10.1001/jamadermatol.2022.1185
- Akses
- Open Access ✓